Literature DB >> 34018168

Pre-and Post-Surgical Health-Related Quality of Life Evaluation of Spheno-orbital Meningioma Patients Based on EORTC QLQ-C30 Questionnaire at Dr. Cipto Mangunkusumo General Hospital.

Renindra Ananda Aman1, Kumara Wisyesa1, Aryandhito Widhi Nugroho1, Syaiful Ichwan1, David Tandian1, Samsul Ashari1, Setyo Widi Nugroh1.   

Abstract

OBJECTIVE: Health-related quality of life (HRQoL) has become an important outcome for neurosurgical patients underwent surgery. The authors utilized the European Organization for Research and Treatment of Cancer Quality of Life Core Questionnaire (EORTC QLQ C-30) to assess the quality of life of spheno-orbital meningiomas patients after surgery in one national central referral hospital in Indonesia.
METHODS: In this cross-sectional study, medical record-based data of 40 spheno-orbital meningioma patients who underwent surgery at Dr. Cipto Mangunkusumo General Hospital, Jakarta, Indonesia from October-December 2016 were analyzed. Differences between pre-and postsurgical EORTC scores was examined using the Student's t test.
RESULTS: There was a statistically significant increase of EORTC QLQ-C30 scores in global health status, role functioning, emotional functioning, cognitive functioning, and social functioning variables, and statistically significant decrease for clinical symptoms variables.
CONCLUSION: Evidently, there was improvement in HRQoL in spheno-orbital meningiomas patients after surgery, in whom EORTC QLQ-C30 can be used to assess the HRQoL prior to and after surgical procedures.

Entities:  

Keywords:  brain tumor; EORTC QLQ C-30; sphenoorbital meningioma; quality of life.

Year:  2020        PMID: 34018168

Source DB:  PubMed          Journal:  Acta Neurol Taiwan        ISSN: 1028-768X


  1 in total

1.  Preoperative nonmedical predictors of functional impairment after brain tumor surgery.

Authors:  Silvia Schiavolin; Arianna Mariniello; Morgan Broggi; Francesco DiMeco; Paolo Ferroli; Matilde Leonardi
Journal:  Support Care Cancer       Date:  2022-01-09       Impact factor: 3.359

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.